Sodium stibogluconate

Sodium stibogluconate

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	IV only
ATC code	P01CB02 (WHO) Template:ATCvet
Legal status
Legal status	UK: POM (Prescription only)
Identifiers
IUPAC name 2,4:2',4'-O-(oxydistibylidyne)bis[D-gluconic acid]
CAS Number	16037-91-5 N
PubChem CID	16685683
DrugBank	DB05630 Y
ChemSpider	21106382 Y
UNII	V083S0159D
KEGG	D00582 Y
ChEMBL	ChEMBL367144 N
NIAID ChemDB	007935
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C12H38Na3O26Sb2
Molar mass	910.9 g/mol
3D model (JSmol)	Interactive image
SMILES [Na+].[Na+].[Na+].O=[Sb]2(O[Sb]1(=O)OC([C@H](O)CO)[C@H](O)[C@@H](O1)C([O-])=O)O[C@@H]([C@H](O)[C@@H](O2)C([O-])=O)[C@H](O)CO
InChI InChI=1S/2C6H10O7.3Na.3O.2Sb/c2*7-1-2(8)3(9)4(10)5(11)6(12)13;;;;;;;;/h2*2-5,7-8,10H,1H2,(H,12,13);;;;;;;;/q2*-2;3*+1;;;;2*+2/p-2/t2-,3?,4+,5-;2-,3-,4+,5-;;;;;;;;/m11......../s1 Y Key:RTLKTTNTVTVWPV-UQCYVGCHSA-L Y
NY (what is this?)  (verify)

WikiDoc Resources for Sodium stibogluconate
Articles
Most recent articles on Sodium stibogluconate Most cited articles on Sodium stibogluconate Review articles on Sodium stibogluconate Articles on Sodium stibogluconate in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Sodium stibogluconate Images of Sodium stibogluconate Photos of Sodium stibogluconate Podcasts & MP3s on Sodium stibogluconate Videos on Sodium stibogluconate
Evidence Based Medicine
Cochrane Collaboration on Sodium stibogluconate Bandolier on Sodium stibogluconate TRIP on Sodium stibogluconate
Clinical Trials
Ongoing Trials on Sodium stibogluconate at Clinical Trials.gov Trial results on Sodium stibogluconate Clinical Trials on Sodium stibogluconate at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Sodium stibogluconate NICE Guidance on Sodium stibogluconate NHS PRODIGY Guidance FDA on Sodium stibogluconate CDC on Sodium stibogluconate
Books
Books on Sodium stibogluconate
News
Sodium stibogluconate in the news Be alerted to news on Sodium stibogluconate News trends on Sodium stibogluconate
Commentary
Blogs on Sodium stibogluconate
Definitions
Definitions of Sodium stibogluconate
Patient Resources / Community
Patient resources on Sodium stibogluconate Discussion groups on Sodium stibogluconate Patient Handouts on Sodium stibogluconate Directions to Hospitals Treating Sodium stibogluconate Risk calculators and risk factors for Sodium stibogluconate
Healthcare Provider Resources
Symptoms of Sodium stibogluconate Causes & Risk Factors for Sodium stibogluconate Diagnostic studies for Sodium stibogluconate Treatment of Sodium stibogluconate
Continuing Medical Education (CME)
CME Programs on Sodium stibogluconate
International
Sodium stibogluconate en Espanol Sodium stibogluconate en Francais
Business
Sodium stibogluconate in the Marketplace Patents on Sodium stibogluconate
Experimental / Informatics
List of terms related to Sodium stibogluconate

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of drugs known as the pentavalent antimonials because they contain antimony in its oxidation state of 5. Sodium stibogluconate is marketed under the name Pentostam. In parts of the world resistance has limited the utility of sodium stibogluconate, in which cases amphotericin or miltefosine is used instead.

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

Side effects

Sodium stibogluconate is exceedingly phlebotoxic. One of the practical problems is that after a few doses it can become exceedingly difficult to find a vein in which to inject the drug. The insertion of a PICC does not prevent the problem and can instead exacerbate it: the entire vein along the course of the PICC line can become inflamed and thrombose. Large doses of sodium stibogluconate are often administered as dilute solutions

Pancreatitis is a common problem and the serum amylase or lipase should be monitored twice weekly; there is no need to stop treatment if the amylase remains less than four times the upper limit of normal; if the amylase rises above the cut-off then treatment should be interrupted until the amylase falls to less than twice the upper limit of normal, whereupon treatment can be resumed. Cardiac conduction disturbances are less common, but ECG monitoring while the medicine is injected is advisable and changes quickly reverse after the drug is stopped or the infusion rate is decreased.

The drug can be given intramuscularly but is exceedingly painful when given by this route. It can also be given intralesionally when treating cutaneous leishmaniasis (i.e., injected directly into the area of infected skin) and again, this is exceedingly painful and does not give results superior to intravenous administration.

Sodium stibogluconate can also cause a reduced appetite, metallic taste in mouth, nausea, vomiting, diarrhoea, headache, tiredness, joint pains, muscle aches, dizziness, and anaphylaxis.

Dosing

Sodium stibogluconate is available in the United Kingdom as Pentostam, where it is manufactured by GlaxoSmithKline. It is available in the United States on a named-patient basis from the Centers for Disease Control and Prevention (CDC).

The dose of sodium stibogluconate is by slow intravenous infusion (at least five minutes with cardiac monitoring). The injection are stopped if there is coughing or central chest pain. The chemotherapeutic index was established by Leonard Goodwin during the Second World War when a treatment was urgently required for Allied troops during the invasion of Sicily.

The duration of treatment is usually 10 to 21 days and depends on the species of Leishmania and the type of infection (cutaneous or visceral).

Chemical structure

The chemical structure of sodium stibogluconate is somewhat ambiguous, and the structure shown above is idealized. Its solutions may contain multiple antimony compounds, although this heterogeneity may be unimportant. It has been speculated that the active species contains only a single antimony centre.

Pharmacokinetics

Although antimony itself is a cause of heavy metal poisoning, stibogluconate does not appear to accumulate in the body and is excreted by the kidneys.

References

• British National Formulary
• The Merck Index, 12th Edition. 742